Posted in

How are Active Pharmaceutical Ingredients used in inhalable drugs?

If you’ve ever sat down with an asthma inhaler, taken a puff of a COPD maintenance drug, or wondered why some allergy relief works so much faster than a pill you swallow, you’re interacting with active pharmaceutical ingredients (APIs) in inhalable drugs. As someone who’s spent over a decade working in API manufacturing—first in a lab, then leading customer partnerships as an ingredient supplier—I’ve seen firsthand how these small, powerful molecules don’t just “go into an inhaler” but are carefully engineered to do exactly what they’re supposed to, when they’re supposed to. Let’s break this down the way we do with our clients, with the real, messy, science-backed details that matter most for anyone buying APIs for inhalable products. Active Pharmaceutical Ingredients

First, let’s set why inhalable APIs are different from the ones you take orally. When you swallow a pill, your stomach breaks it down, your liver filters most of it out, and only a tiny fraction reaches your lungs. For respiratory conditions like asthma or COPD, that means you’d need a huge dose just to get a little where it counts—and that dose would raise the risk of side effects, like a dry mouth or increased heart rate. Inhalable APIs cut that process out: they go straight to the lungs, where they work on inflamed airways almost immediately. But that simplicity is a trick. The API isn’t just dumped into an inhaler; it’s part of a precise system that has to target the right spot, stay there long enough to work, and avoid getting into the bloodstream too much.

Let’s start with the types of inhalable APIs, because not all are made the same. The two most common categories are bronchodilators and corticosteroids, and each has its own manufacturing needs. Bronchodilators, like albuterol (the fast-acting rescue inhaler most people with asthma know), relax the smooth muscle around airways to open them up quickly. Corticosteroids, like fluticasone, reduce inflammation over time—these are the maintenance inhalers you use every day to prevent attacks. For both, the API has to be in a form that can be aerosolized, turned into tiny particles you can breathe deep into your lungs.

Here’s where our work as an API supplier comes in. We don’t just produce a raw powder and ship it. We have to engineer that powder’s particle size, shape, and surface chemistry to match exactly what inhaler devices require. A particle that’s too big (over 5 micrometers, roughly) will get stuck in your mouth or throat—you’ll swallow it, and it’ll go through that same oral absorption process we talked about, leading to wasted API and more side effects. A particle too small (under 1 micrometer) will go past the lungs into the bloodstream, where it can cause unintended effects like increased blood pressure or immune suppression. We aim for 1 to 5 micrometers: that’s the sweet spot that lingers in the airways, where it’s needed most.

Take albuterol sulfate, a bronchodilator we supply to several major inhaler manufacturers. Its particle size isn’t just ground down randomly. We use a process called jet milling, where compressed air blasts the raw API into tiny, uniform particles. It’s not as simple as just grinding—too much heat during milling can break down the API’s molecular structure, making it ineffective. That’s a detail many newer suppliers overlook, but it’s the difference between an inhaler that works and one that doesn’t. For fluticasone propionate, a corticosteroid, we do additional processing: we coat the API particles with a thin layer of a biologically inert excipient, like lactose. This coating helps the particles stick to the airway walls longer, so the API can exert its anti-inflammatory effect instead of being exhaled right away. That extra step adds a lot of value for our customers, because it means their inhalers don’t need as high a dose to work.

Next, how is the API actually incorporated into the inhalable drug product? There are two main device types that use APIs: metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), and each has very different requirements for the API. MDIs, the most common type of rescue inhaler, mix the API with a propellant (usually hydrofluoroalkane, or HFA, replacing the old ozone-depleting chlorofluorocarbons, or CFCs) and a small amount of excipients to stabilize the mixture. The API here has to be soluble in the propellant, or suspended evenly—if it clumps together, the inhaler will spurt out big, uneven puffs, leading to inconsistent doses. That’s another place our API expertise matters: we test every batch of albuterol we supply for dispersibility in HFA, so our customers don’t have to spend months fixing clumping issues in their final device.

DPIs, on the other hand, don’t use a propellant. They rely on the user’s breath to pull the API particles into their lungs. That means the API has to be extremely fine, but not so fine that it’s hard to inhale. We manufacture APIs for DPIs with even tighter particle size controls—often within a 0.5 to 3 micrometer range—because if a user takes a shallow breath, a particle that’s too big won’t make it deep enough. We also supply APIs blended with lactose powder as a carrier: the lactose particles are bigger, so they sit in the inhaler until the user inhales, which separates the smaller API particles so they don’t clump. This blend has to be consistent, too—we test the ratio of API to lactose for every batch, so our customers know exactly how much API is in each dose, down to the milligram.

Now, let’s talk about how the API works once it’s in the lungs, because that’s where the science gets interesting. For bronchodilators, like albuterol, the API binds to beta-2-adrenergic receptors on the smooth muscle cells around the airways. That binding triggers a signal that relaxes the muscle, opening the airways within 5 to 15 minutes—perfect for a rescue inhaler. For corticosteroids, like fluticasone, the API binds to glucocorticoid receptors in the immune cells that cause airway inflammation. This binding suppresses the production of inflammatory chemicals, like cytokines, over days to weeks, which is why maintenance inhalers aren’t for immediate relief.

But there’s a balance here: we want the API to act locally in the lungs, not get into the systemic circulation. That’s called lung-targeted delivery, and it’s a big focus for our team. We adjust the API’s molecular weight and lipophilicity (how “fat-soluble” it is) to make sure it doesn’t get absorbed into the bloodstream too easily. Corticosteroids, for example, are designed to be highly lipophilic so they stick to the lung tissue, not move into the blood. As an API supplier, we test every batch of our corticosteroids for systemic absorption in vitro, using human lung tissue models, to make sure our customers can count on low side effect rates.

I should also mention a newer area we’re working on: biologic APIs for inhalable drugs. For a long time, inhalable drugs were only small molecules, but now, biologic APIs like monoclonal antibodies are being developed for respiratory conditions like pulmonary fibrosis or even COVID-19-related lung damage. These biologics have their own set of challenges: they’re much larger molecules, so particle size is trickier to control, and they can break down easily during manufacturing. We’ve invested in a new biologic API processing line specifically for inhalable products, because our customers are coming to us with ideas that didn’t exist 10 years ago. For example, a few years ago, a startup came to us with an idea for an inhalable monoclonal antibody to treat cystic fibrosis. We worked with them to optimize the biologic’s particle size and stability, so it could be aerosolized without breaking down. That’s the kind of problem-solving we do that goes beyond just supplying a raw API.

Of course, none of this works without quality control. For inhalable APIs, the standards are higher than for many other APIs, because a tiny error in particle size or purity can lead to a inhaler that’s ineffective or even dangerous. We test every batch for impurities—like residual solvents from manufacturing, or microbial contamination—to make sure they meet global pharmacopeia standards, like USP, EP, or JP. We also do in vivo testing with animal models to measure how much of the API reaches the lungs, and how much is absorbed into the bloodstream. This isn’t just a box-ticking exercise; it’s how we build trust with our customers. A few years ago, one of our long-time clients had a issue with a competitor’s API that had inconsistent particle size, leading to 10% of their inhaler doses being too big or too small. We were able to step in, provide a batch of our API with tighter controls, and help them get their product back on the market quickly. That’s the value of working with an API supplier who understands the end product, not just the API itself.

Now, let’s address a common question we get: why does the API supplier matter more for inhalable drugs than for, say, oral drugs? If a pill is wrong, you might get a stomach ache or it doesn’t work. But an inhalable drug that’s wrong can be life-threatening. If the API particles are too big, the user might not get enough relief, leading to an asthma attack. If they’re too small, the systemic side effects could be serious—especially for long-term users of maintenance inhalers. Also, regulatory agencies like the FDA and EMA have very specific requirements for inhalable APIs, because they’re administered directly to the lungs. As a supplier, we have to maintain current good manufacturing practices (cGMP) that are tailored to inhalable APIs, which means separate production lines, rigorous testing, and detailed documentation for every batch. We don’t cut corners here—we know that the drugs we supply get into patients’ lungs, and their lives depend on it.

Looking ahead, the demand for inhalable APIs is only going to grow. More people are being diagnosed with asthma and COPD, and there’s a push to develop inhalable drugs for other conditions, like diabetes or even migraine headaches. Inhalable insulin, for example, has been around for a while, but newer formulations are being developed that work better and have fewer side effects. As an API supplier, we’re investing in R&D to develop APIs for these new products, and to improve existing ones—like making inhaler APIs that last longer, so patients don’t have to use their inhalers as often.

If you’re a pharmaceutical manufacturer looking for reliable, high-quality APIs for inhalable drugs, the details I’ve talked about—particle size engineering, stability testing, regulatory compliance, and end-to-end support—are what set the right supplier apart. We don’t just ship a powder; we partner with you to make sure your inhalable drug works as intended, for every patient who uses it.

For inquiries about our inhalable APIs, please reach out to our team to discuss your specific project needs.

Biochemical References:

  1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024.
  2. US Pharmacopeia (USP). <601> Aerosolized Drug Products for Inhalation, 2023.
  3. Labiris, N. R., & Dolovich, M. B. (2003). Pulmonary drug delivery: part 1: factors affecting therapeutic effectiveness of aerosolized medications. British Journal of Clinical Pharmacology, 56(6), 588-599.
  4. European Medicines Agency (EMA). Guideline on Pharmaceutical Development of Inhalation Products, 2015.
  5. Byron, P. R., et al. (2015). Progress in inhaled drug delivery for respiratory and systemic diseases. Advanced Drug Delivery Reviews, 85, 2-15.

Dayang Chem (Hangzhou) Co., Ltd.
As one of the most professional active pharmaceutical ingredients manufacturers and suppliers in China, we’re featured by quality products and good service. Please feel free to buy customized active pharmaceutical ingredients made in China here from our factory. For price consultation, contact us.
Address: 9/F, Unit 2, 259# Wensan Road, Xihu District, Hangzhou Zhejiang, China
E-mail: sales@dayangchemcn.com
WebSite: https://www.dayangchem-cn.com/